

20 January 2014 EMA/10115/2014 Procedure Management & Business Support Division

Monthly statistics report: December 2013

Medicinal products for human use (cumulative figures for the year to date)

This document provides current information related to the volume and evaluation of marketing authorisation and post-authorisation applications for medicinal products for human use received by the European Medicines Agency.

The purpose is only to provide ongoing factual information. Commentaries and analysis are provided in the Agency's annual reports.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom **Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8416 **E-mail** info@ema.europa.eu **Website** www.ema.europa.eu



An agency of the European Union


 $\textcircled{\mbox{\sc b}}$ European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged.

	2010		2011		2012		2013 ⁺	
	Started	Finalised	Started	Finalised	Started	Finalised	Started	Finalised
Non-orphan medicinal products								
New products	34	21	46	37	44	35	48	46
Advanced-therapy medicinal products	0	0	1	0	1	0	0	2
Advanced-therapy Art. 29 transition products	0	0	1	0	2	0	N/A	0
Paediatric-use (PUMA) products	1	0	1	1	0	0	1	0
Well-established use, abridged, hybrid and non-prescription switch products	9	6	8	8	5	6	6	4
Generic products	33	20	25	34	16	13	5	16
Similar biological products	1	1	3	0	8	0	1	4
Sub-total product applications	78	48	85	80	76	54	61	72
Orphan medicinal products								
New products	12	6	14	11	19	11	16	14
Advanced-therapy medicinal products	1	0	0	1	0	0	2	0
Total product applications	90	54	99	91	95	65	79	86

Table 1. Pre-authorisation: Marketing-authorisation applications^{*}

Finalised applications exclude applications withdrawn prior to opinion.

Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.



Marketing authorisation application evaluations started by type of application

[†] Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.


	2010	2011	2012	2013 [†]
Positive opinions	51	87	57	79
Opinions recommending conditional ** marketing authorisation	4	3	3	4
Negative opinions	2	4	8	7
** Opinions after accelerated assessment	1	0	1	5
Applications withdrawn prior to opinion	12	13	10	8
Re-examinations requested	3	5	2	10


Table 2. Pre-authorisation: Outcome of the evaluation of marketing authorisation applications *

* Outcome of the evaluation leading to an initial opinion, excluding the outcome of a re-examination where applicable.

** Included in the figures for positive opinions.

[†] Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.





[†] Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.

Table 3. Scientific services

	2010		2011		2012		2013 [†]	
	Started	Finalised	Started	Started	Started	Finalised	Started	Finalised
Compassionate-use opinions	1	2	0	0	0	0	2	2
Art. 58 (WHO) scientific opinions	1	0	1	0	1	2	1	1
Opinions on ancillary medicinal substances in medical devices*	3	0	3	2	0	2	3	1
Plasma master file (includes initial certification, variations and annual re-certification)	22	19	30	37	22	28	19	13
Vaccine antigen master file	0	0	0	0	0	0	0	0

* Consultation in accordance with Council Directive 93/42/EEC concerning medical devices as amended by Directive 2000/70/EC as regards medical devices incorporating stable derivates of human blood or plasma and Directive 2001/14/EC.

[†] Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.


	2010		2011		2012		2013 [†]	
	Received	Finalised	Received	Finalised	Received	Finalised	Received	Finalised
Type IA variations	2,057	1,711	2,875	2,847	2,889	2,798	2,922	2,886
Type IB variations	1,093	852	1,260	1,193	1,468	1,416	1,958	1,597
Type II variations	966	942	873	918	1,012	906	961	946
Extensions of marketing authorisation	29	26	31	24	16	17	16	18
Grouped applications*	51%	38%	61%	61%	63%	61%	61%	61%
Multi-product Type IA groups	41	31	99	101	111	108	119	118
Worksharing variation applications	111	58	112	115	120	123	123	112
Annual reassessments	19	20	18	16	16	14	18	16
Renewals**	67	27	67	62	76	77	98	77

Table 4. Post-authorisation: Variations, renewals and annual reassessments

 $^{\ast}\,$ Excluding groups in worksharing or multi-product Type IA groups.

 ** Includes renewals of conditional marketing authorisations.

[†] Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.



Post-authorisation: Variations, renewals and annual reassessments